Severe Toxicity reported in MDR-TB patients with Linezolid >2mg/L, study finds.
A recent study revealed that >2mg/L concentrations of Linezolid are associated with the development of treatment-emergent toxicity in patients treated for Multi drug resistant Tuberculosis (MDR-TB). The study was published in the journal Clinical Infectious Diseases, 2022.
MDR-TB when treated with Linezolid is characterized by high rates of adverse events. The evidence on therapeutic drug monitoring to predict toxicity is scarce. Researchers conducted a study to evaluate the association of linezolid concentrations with severe toxicity.
The study was conducted between 2011 and 2017. It was a retrospective assessment of consecutive patients on Linezolid for MDR-TB. Severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation was the primary outcome. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates.
The key findings of the study were:
- SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95%CI 0.30-0.49).
- A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%).
- The adjusted hazard ratio for SMT was 2.35 (95%CI 1.26–4.38, p = 0.01) in patients with a mean trough concentration >2 mg/L and 2.63 (95%CI 1.55–4.47, p < 0.01) for SMT after the first detection of a trough concentration >2 mg/L.
- In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering of elevated trough concentrations did not restore baseline risk.
Thus, the researchers concluded that Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR-TB. They further added that for any patient with trough concentrations above 2 mg/L an individual risk-benefit assessment on the continuation of linezolid treatment is warranted.
For the Full Article, Click here: https://doi.org/10.1093/cid/ciac485
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.